1Nabavi, B, Mitchell, AJ, Nutt, D. A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta-analysis of 52 interview-based studies of psychiatric population. EBioMedicine 2015; 2(10): 1405–19.
2Preti, A, Vrublevska, J, Veroniki, AA, Huedo-Medina, TB, Fountoulakis, KN. Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis. Evid Based Ment Health 2016; 19(3): 73–81.
3Amerio, A, Stubbs, B, Odone, A, Tonna, M, Marchesi, C, Ghaemi, SN. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord 2015; 186: 99–109.
4Joslyn, C, Hawes, DJ, Hunt, C, Mitchell, PB. Is age of onset associated with severity, prognosis, and clinical features in bipolar disorder? A meta-analytic review. Bipolar Disord 2016; 18(5): 389–403.
5Das, A. Anxiety disorders in bipolar I mania: prevalence, effect on illness severity, and treatment implications. Indian J Psychol Med 2013; 35(1): 53–9.
6Kim, SW, Berk, L, Kulkarni, J, Dodd, S, de Castella, A, Fitzgerald, PB, et al. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder. J Affect Disord 2014; 166: 243–8.
7Hunt, GE, Malhi, GS, Cleary, M, Lai, HM, Sitharthan, T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: systematic review and meta-analysis. J Affect Disord 2016; 206: 321–30.
8Hunt, GE, Malhi, GS, Cleary, M, Lai, HM, Sitharthan, T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: systematic review and meta-analysis. J Affect Disord 2016; 206: 331–49.
9Robinson, J, Sareen, J, Cox, BJ, Bolton, J. Self-medication of anxiety disorders with alcohol and drugs: results from a nationally representative sample. J Anxiety Disord 2009; 23(1): 38–45.
10Perroud, N, Cordera, P, Zimmermann, J, Michalopoulos, G, Bancila, V, Prada, P, et al. Comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar disorder in a specialized mood disorders outpatient clinic. J Affect Disord 2014; 168: 161–6.
11Singh, JB, Zarate, CA Jr. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord 2006; 8(6): 696–709.
12Schaffer, A, McIntosh, D, Goldstein, BI, Rector, NA, McIntyre, RS, Beaulieu, S, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012; 24(1): 6–22.
13Ketter, TA, Miller, S, Dell'Osso, B, Calabrese, JR, Frye, MA, Citrome, L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord 2014; 169(Suppl 1): S24–33.
14Baldessarini, R, Henk, H, Sklar, A, Chang, J, Leahy, L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008; 59(10): 1175–83.
15Serna, MC, Real, J, Cruz, I, Galván, L, Martin, E. Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance. BMC Public Health 2015; 15: 1184.
16Mitchell, AJ. Depressed patients and treatment adherence. Lancet 2006; 367(9528): 2041–3.
17Keck, PE Jr, McElroy, SL, Strakowski, SM, Bourne, ML, West, SA. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997; 33(1): 87–91.
18Fountoulakis, KN, Vieta, E, Young, A, Yatham, L, Grunze, H, Blier, P, et al. The International College of Neuropsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 4: unmet needs in the treatment of bipolar disorder and recommendations for future research. Int J Neuropsychopharmacol 2017; 20(2): 196–205.
19Rosenberg, KP, Bleiberg, KL, Koscis, J, Gross, C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003; 29(4): 289–96.
20Kaufman, KR, Wong, S, Sivaraaman, K, Anim, C, Delatte, D. Epilepsy and AED-induced decreased libido – the unasked psychosocial comorbidity. Epilepsy Behav 2015; 52(Pt A): 236–8.
21Amsterdam, JD, Garcia-Espana, F, Goodman, D, Hooper, M, Hornig-Rohan, M. Breast enlargement during chronic antidepressant therapy. J Affect Disord 1997; 46: 151–6.
22Kaufman, KR, Podolsky, D, Greenman, D, Madraswala, R. Antidepressant-selective gynecomastia. Ann Pharmacother 2013; 47(1): e6.
23Harvey, BH, Slabbert, FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 2014; 29(6): 503–16.
24Fava, GA, Gatti, A, Belaise, C, Guidi, J, Offidani, E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84(2): 72–81.
25Narayan, V, Haddad, PM. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol 2011; 25(3): 306–13.
26Post, RM, Leverich, GS, Kupka, RW, Keck, PE Jr, McElroy, SL, Altshuler, LL, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010; 71(7): 864–72.
27Drancourt, N, Etain, B, Lajnef, M, Henry, C, Raust, A, Cochet, B, et al. Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand 2013; 127(2): 136–44.
28Altamura, AC, Dell'Osso, B, Berlin, HA, Buoli, M, Bassetti, R, Mundo, E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2010; 260(5): 385–91.
29Patel, R, Shetty, H, Jackson, R, Broadbent, M, Stewart, R, Boydell, J, et al. Delays before diagnosis and initiation of treatment in patients presenting to mental health services with bipolar disorder. PLoS One 2015; 10(5): e0126530.
30Merikangas, KR, Jin, R, He, JP, Kessler, RC, Lee, S, Sampson, NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68(3): 241–51.
31Yen, S, Stout, R, Hower, H, Killam, MA, Weinstock, LM, Topor, DR, et al. The influence of comorbid disorders on the episodicity of bipolar disorder in youth. Acta Psychiatr Scand 2016; 133(4): 324–34.
32McIntyre, RS, Konarski, JZ, Yatham, LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004; 19(6): 369–86.
33Malhi, GS, Bargh, DM, McIntyre, R, Gitlin, M, Frye, MA, Bauer, M, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012; 14(Suppl 2): 1–21.
34Sidor, MM, MacQueen, GM. An update on antidepressant use in bipolar depression. Curr Psychiatry Rep 2012; 14(6): 696–704.
35Freeman, MP, Freeman, SA, McElroy, SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002; 68(1): 1–23.
36Malhi, GS, Bargh, DM, Cashman, E, Frye, M, Gitlin, M. The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord 2012; 14(Suppl 2): 66–89.
37Mago, R, Borra, D, Mahajan, R. Role of adverse effects in medication nonadherence in bipolar disorder. Harv Rev Psychiatry 2014; 22(6): 363–6.
38Kaufman, KR. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav 2011; 21(1): 1–11.
39Rahmani, S, Turton, P, Shaaban, A, Dall, B. Overview of gynecomastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. Breast J 2011; 17(3): 246–55.
40Bowman, JD, Kim, H, Bustamante, JJ. Drug-induced gynecomastia. Pharmacotherapy 2012; 32(12): 1123–40.
41Damsa, C, Bumb, A, Bianchi-Demicheli, F, Vidailhet, P, Sterck, R, Andreoli, A, et al. ‘Dopamine-dependent’ side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004; 65(8): 1064–8.
42Bergman, D, Futterweit, W, Segal, R, Sirota, D. Increased oestradiol in diazepam related gynaecomastia. Lancet 1981; 2(8257): 1225–6.
43Jelenkovic, AV, Macukanovic-Golubovic, LDj. Diazepam-associated gynecomastia. Ann Pharmacother 2005; 39(1): 201.
44Allen, RC, Wallace, AM, Royce, M. Marinol-induced gynecomastia: a case report. Am J Med 2007; 120(10): e1.
45Basaria, S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95(4): 1533–43.
46Boggs, DL, Ranganathan, M, Boggs, AA, Bihday, CM, Peluse, BE, D'Souza, DC. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. Prim Care Companion CNS Disord 2013; 15(4): 13l01519.
47Kaneda, Y, Morimoto, T, Fujii, A. Gynecomastia induced by treatment with tandospirone, a 5-HT1A agonist. J Psychiatry Neurosci 2001; 26(2): 152–3.
48Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, Roberts, EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45.
49Hosenbocus, S, Chahal, R. SSRIs and SNRIs: a review of the discontinuation syndrome in children and adolescents. J Can Acad Child Adolesc Psychiatry 2011; 20(1): 60–7.
50Feighner, JP, Boyer, WF. Serotonin-1A anxiolytics: an overview. Psychopathology 1989; 22(Suppl 1): 21–6.
51Taylor, DP. Serotonin agents in anxiety. Ann N Y Acad Sci 1990; 600: 545–56.
52Howland, RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2010; 48(7): 9–12.